News - Alimera Sciences, pSivida

Filter

Current filters:

Alimera SciencespSivida

Popular Filters

FDA calls for new trial before it can approve Alimera’s Iluvien

FDA calls for new trial before it can approve Alimera’s Iluvien

18-10-2013

USA-based ophthalmic biopharma specialist Alimera Sciences says that it has received a third Complete…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

UK’s NICE recommends Iluvien for DME

02-10-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final draft…

Alimera SciencesEuropeIluvienOphthalmicsPharmaceuticalpSividaRegulation

pSivida and Alimera's Iluvien debuts in Germany; New data on Novartis' Lucentis

08-05-2013

USA-based pSivida Corp (Nasdaq: PSDV), a leader in developing sustained release, drug delivery products…

Alimera SciencesIluvienLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalpSividaResearch

Another FDA rejection for Alimera’s DME drug Iluvien

14-11-2011

Shares of US ophthalmic drug develop Alimera Sciences (Nasdaq: ALIM) plunged nearly 73% to $2 on Friday,…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

Back to top